
|Videos|February 14, 2014
Pazopanib for the Treatment of Soft Tissue Sarcoma
Author(s)Vicki Keedy, MD
Vicki Keedy, MD, Assistant Professor of Medicine, Clinical Director, Sarcoma Program, Vanderbilt-Ingram Cancer Center, discusses pazopanib for the treatment of soft tissue sarcoma.
Advertisement
Clinical Pearls
Vicki Keedy, MD, Assistant Professor of Medicine, Clinical Director, Sarcoma Program, Vanderbilt-Ingram Cancer Center, discusses pazopanib for the treatment of soft tissue sarcoma.
- Pazopanib was recently approved for the treatment of patients with advanced soft tissue sarcoma who have received prior chemotherapy
- Treatment with pazopanib quadrupled progression-free survival compared with placebo
- Drugs to treat soft tissue sarcoma are generally toxic
- Pazopanib is well tolerated, with some instances of extended fatigue
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
3
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
4
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
5








































